Off Script: A Pharma Manufacturing Podcast Pharma Manufacturing

By integrating a Quality by Design (QbD) approach, developers can design robust packaging from the outset,  drastically reducing development time and costs. Understanding how moisture affects a product is key, allowing developers to use industry-accepted and validated models to predict and address potential stability issues early in the design phase, thereby reducing the need for prolonged probe stability testing and potential reformulations or packaging redesign. 
To understand more about the issues at hand, senior editor Andrea Corona recently spoke with Adrian Possumato, president and Chris Gilmor, director of sales, at Sanner of America.
Learn more about Sanner of America: https://www.sanner-group.com/
 

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: 
The good — FDA AdComm backs Eli Lilly Alzheimer’s drugThe bad — Pfizer gene therapy fails phase 3 Duchenne trialThe ugly — Talc plaintiffs seek restraining order on J&J bankruptcy tactic

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: 
The good —  AstraZeneca’s Tagrisso delivers 84% progression-free survival in trialThe bad — BMS to let go of 863 employees at NJ site The ugly — FDA inspection uncovers multiple violations at Jiangsu Hengrui Pharmaceuticals site

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: 
The good — J&J depression drug aces late-stage trialThe bad — Takeda plans layoffs at Massachusetts sitesThe ugly —  FDA delays review of Sanofi-Regeneron's Dupixent in COPD

When the pandemic hit and Americans found themselves looking to China for critical medical supplies, the idea of reshoring — a concept that had drifted along the currents of the manufacturing sector for over a decade — embedded itself into pharma discourse with renewed luster.
During this podcast, Chief Content Director Karen Langhauser will share a summary of our most recent cover story, Mining pharma's reshoring rush, and discuss where the industry stands amid the U.S. movement to bring the manufacturing of generic drugs, APIs and ingredients home.
 

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: 
The good —  FDA approves first interchangeable biosims to Regeneron Eylea The bad — Evotec exits gene therapyThe ugly —  J&J reports deaths in early-stage radioligand trial